$BTAI --Analyst Actions: Canaccord Genuity Lifts Price Target on BioXcel Therapeutics to $120 From $71 on 'Robust' BXCL501 Trial Data; Buy Rating Kept BY MT Newswires— 11:19 AM ET 07/21/2020
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.